IP Library Granted Patent US 8,071,318
Granted Patent B2
US 8,071,318 · App. 10/771,283 · Granted Dec 6, 2011

High throughput method and system for screening candidate compounds for activity against target ion channels

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,318
App. No.
10/771,283
Granted
Dec 6, 2011
Kind
B2
Abstract

Drug candidate screening methods are applied to discover compounds with activity against ion channel targets. The method may include modulating the transmembrane potential of host cells in a plurality of sample wells with a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.

Claims (12)

1. A method of screening a plurality of drug candidate compounds against a target ion channel comprising:

expressing said target ion channel in a population of host cells;

placing a plurality of said host cells into each of a plurality of sample wells;

adding a candidate drug compound to at least one of said plurality of sample wells;

affecting the target ion channel by modulating a transmembrane potential of said host cells in said at least one well with an application of a series of electric field pulses applied with extracellular electrodes extending down into said at least one well so as to set said transmembrane potential to a level suitable for a specific ion channel activation state or transition between states, wherein the frequency of the electric field pulses (f) is within the range τ M −1 ≦f≦τ b −1 where τ M is a time constant for decay of transmembrane potential changes, and τ b is an average target ion channel open time, wherein the pulses at said frequency cause a sustained transmembrane potential change via a stepwise accumulation or loss of ions over the course of said series of pulses; and

detecting transmembrane potential characteristics of said plurality of cells over an area of observation in said at least one well to detect an effect of said candidate drug compound on said target ion channel.

2. The method of claim 1 , additionally comprising selecting a host cell line having a normal resting transmembrane potential corresponding to a second pre-selected voltage dependent state of said target ion channel.

3. The method of claim 1 , wherein said electric fields are biphasic.

4. The method of claim 1 , wherein electric fields cause said target ion channel to cycle between different voltage dependent states.

5. The method of claim 1 , wherein said electric fields cause said target ion channel to open.

6. The method of claim 1 , wherein said electric fields cause said target ion channel to be released from inactivation.

7. The method of claim 1 , wherein said plurality of said host cells comprise a voltage sensor selected from the group consisting of a FRET based voltage sensor, an electrochromic transmembrane potential dye, a transmembrane potential redistribution dye, an ion sensitive fluorescent or luminescent molecule and a radioactive ion.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →